P – AML patients with favorable prognosis [<60 years, with white blood cell count at diagnosis <30,000 or <50,000/mm3 with cytogenetics t(8;21)/AML1-ETO/RUNX1-RUNX1T1, inv(16)/t(16;16)/CBFbeta/MYH11, Core binding factor leukemia, FLT3-negative or FLT3-ITD-negative/NPM1-mutated]

I – Use of cytarabine (400 mg/m2, 2 g/m2/day, 3 g/m2/day 4 g/m2/day, or 6 g/m2/day)

C –

O – Complete remission rate, overall survival, and disease-free survival